Table 4.

Selecting patients for primary endocrine therapy according to degree of ER positivity increases the proportion who have clinical benefit, and reduces the rate of de novo resistance

All ≥ 70 years on primary endocrine therapy (stage 1/2 disease)	Chakrabartia	Johnstonb	Syedc
ER H score	Unselected	H ≥ 100	H ≥ 250
N	68	100	121
CB (at 6 months)	74%	97%	100%
PD (at 6 months) (de novo resistance)	26%	3%	0%

^aChakrabarti et al. [63]

^bJohnston et al. [61]

^cSyed et al. [64]